MX390671B - Composicion de suspension oftalmica. - Google Patents
Composicion de suspension oftalmica.Info
- Publication number
- MX390671B MX390671B MX2017009699A MX2017009699A MX390671B MX 390671 B MX390671 B MX 390671B MX 2017009699 A MX2017009699 A MX 2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A MX 390671 B MX390671 B MX 390671B
- Authority
- MX
- Mexico
- Prior art keywords
- ophthalmic
- composition
- suspension
- ophthalmic suspension
- âμm
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940100654 ophthalmic suspension Drugs 0.000 title 1
- 239000000725 suspension Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000375 suspending agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107696P | 2015-01-26 | 2015-01-26 | |
| PCT/US2016/014872 WO2016123079A1 (en) | 2015-01-26 | 2016-01-26 | Ophthalmic suspension composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017009699A MX2017009699A (es) | 2017-10-23 |
| MX390671B true MX390671B (es) | 2025-03-21 |
Family
ID=55359733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009699A MX390671B (es) | 2015-01-26 | 2016-01-26 | Composicion de suspension oftalmica. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10596107B2 (enExample) |
| EP (5) | EP4268850B1 (enExample) |
| JP (1) | JP2018507252A (enExample) |
| KR (1) | KR102538370B1 (enExample) |
| CN (1) | CN107427464B (enExample) |
| AU (3) | AU2016211745A1 (enExample) |
| BR (1) | BR112017016016B1 (enExample) |
| CA (1) | CA2975106A1 (enExample) |
| ES (5) | ES3031414T3 (enExample) |
| HU (5) | HUE048564T2 (enExample) |
| MX (1) | MX390671B (enExample) |
| PL (5) | PL4082531T3 (enExample) |
| PT (3) | PT3721868T (enExample) |
| SI (1) | SI4268850T1 (enExample) |
| WO (1) | WO2016123079A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3721868T (pt) | 2015-01-26 | 2022-08-12 | Bausch & Lomb | Composição para suspensão oftálmica |
| CA3001955C (en) | 2015-10-16 | 2023-11-28 | Sun Pharma Advanced Research Company Limited | Ophthalmic solution of difluprednate |
| DK3245988T3 (da) | 2016-05-18 | 2024-01-29 | Sonikure Holdings Ltd | System til ultralydsforstærket transskleral levering af lægemidler |
| CA3073195A1 (en) | 2017-08-15 | 2019-02-21 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
| CN113227304A (zh) * | 2018-09-21 | 2021-08-06 | Ps治疗有限公司 | 人工泪液、隐形眼镜和药物载体组合物及其使用方法 |
| JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| JP2022520410A (ja) * | 2019-02-15 | 2022-03-30 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤 |
| JP2023505409A (ja) * | 2019-08-18 | 2023-02-09 | アイビュー セラピューティクス（ズーハイ）カンパニー リミテッド | 持続型の眼用薬物送達システムとしてシクロスポリンミセルを含むｉｎ－ｓｉｔｕゲル |
| KR102271247B1 (ko) * | 2020-11-04 | 2021-06-30 | 삼천당제약주식회사 | 안과용 현탁액 조성물의 제조방법 |
| CN115554238A (zh) * | 2022-10-25 | 2023-01-03 | 苏州欧康维视生物科技有限公司 | 眼用混悬液及其制备方法 |
| CN115887372A (zh) * | 2022-10-25 | 2023-04-04 | 苏州欧康维视生物科技有限公司 | 丙酸氟替卡松混悬液及其制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4996335A (en) | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| US4540930A (en) | 1983-09-12 | 1985-09-10 | Wisconsin Alumni Research Foundation | Plywheel-powered mobile X-ray apparatus |
| ATE151286T1 (de) | 1983-11-14 | 1997-04-15 | Columbia Lab Inc | Bioadhäsive mittel |
| NZ226171A (en) | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| US5192535A (en) | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
| IE63392B1 (en) | 1988-02-08 | 1995-04-19 | Insite Vision Inc | Ophthalmic suspensions |
| US5124154A (en) | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| CA2134376C (en) | 1993-12-20 | 2001-10-23 | Haresh G. Bhagat | Combinations of polymers for use in physiological tear compositions |
| US5556848A (en) * | 1993-12-27 | 1996-09-17 | Senju Pharmaceutical Co., Ltd. | Ophthalmic suspension containing diflupredonate |
| GB9718568D0 (en) * | 1997-09-03 | 1997-11-05 | Chauvin Pharmaceuticals Limite | Compositions |
| TWI227143B (en) | 1999-12-15 | 2005-02-01 | Guo-Jiun Sung | In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method |
| AR033151A1 (es) * | 2001-04-12 | 2003-12-03 | Sucampo Pharmaceuticals Inc | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares |
| US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
| EP2283864A1 (en) * | 2002-07-16 | 2011-02-16 | Elan Pharma International Ltd. | Liquid dosage compositions fo stable nanoparticulate active agents |
| KR20110134525A (ko) | 2003-06-13 | 2011-12-14 | 알콘, 인코퍼레이티드 | 시너지성의 2개의 폴리머 배합물을 포함하는 안과용 조성물 |
| US20050197303A1 (en) | 2003-10-31 | 2005-09-08 | Bausch & Lomb Incorporated | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
| US20050182039A1 (en) | 2004-02-13 | 2005-08-18 | Bausch & Lomb Incorporated | Use of Loteprednol etabonate for the treatment of dry eye |
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| US7919483B2 (en) | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
| US20100234336A1 (en) | 2005-11-14 | 2010-09-16 | Erning Xia | Ophthalmic Compositions |
| US20070110812A1 (en) | 2005-11-14 | 2007-05-17 | Bausch & Lomb Incorporated | Ophthalmic composition for dry eye therapy |
| US20120028947A1 (en) | 2005-11-14 | 2012-02-02 | Erning Xia | Ophthalmic Compositions |
| US8846770B2 (en) * | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
| US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| CN101966143A (zh) | 2009-07-28 | 2011-02-09 | 胡容峰 | 加替沙星温度及pH敏感眼用凝胶的制备与应用 |
| PT2506831E (pt) | 2009-12-03 | 2014-01-08 | Alcon Res Ltd | Suspensões de nanopartículas contendo um polímero de carboxivinilo |
| KR20140069210A (ko) | 2011-09-22 | 2014-06-09 | 보오슈 앤드 롬 인코포레이팃드 | 안과적 겔 조성물 |
| US9056057B2 (en) | 2012-05-03 | 2015-06-16 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| PL3517541T3 (pl) | 2012-05-08 | 2020-12-28 | Nicox Ophthalmics, Inc. | Postać polimorficzna propionianu flutykazonu |
| US8765725B2 (en) * | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| AU2013259150B2 (en) * | 2012-05-11 | 2016-07-14 | Formosa Pharmaceuticals, Inc. | Organic compound nanopowder, production method therefor, and suspension |
| KR20150046300A (ko) | 2012-08-31 | 2015-04-29 | 보오슈 앤드 롬 인코포레이팃드 | 오메가-3 지방산을 함유하는 안과용 조성물 |
| US20150190407A1 (en) | 2014-01-07 | 2015-07-09 | Insite Vision Incorporated | Methods for treatment of postoperative inflammation with reduced intraocular pressure |
| JP6373994B2 (ja) | 2014-07-11 | 2018-08-15 | 富士フイルム株式会社 | 眼科用水性組成物の製造方法 |
| NZ728131A (en) | 2014-07-11 | 2017-09-29 | Fujifilm Corp | Aqueous ophthalmic composition |
| JP6567648B2 (ja) | 2014-07-28 | 2019-08-28 | サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ | 薬物のバイオアベイラビリティーの増加および／または眼作用の持続方法 |
| PT3721868T (pt) | 2015-01-26 | 2022-08-12 | Bausch & Lomb | Composição para suspensão oftálmica |
-
2016
- 2016-01-26 PT PT201663127T patent/PT3721868T/pt unknown
- 2016-01-26 HU HUE18209003A patent/HUE048564T2/hu unknown
- 2016-01-26 PL PL22175139.9T patent/PL4082531T3/pl unknown
- 2016-01-26 JP JP2017558359A patent/JP2018507252A/ja active Pending
- 2016-01-26 EP EP23196938.7A patent/EP4268850B1/en active Active
- 2016-01-26 CN CN201680016825.XA patent/CN107427464B/zh active Active
- 2016-01-26 WO PCT/US2016/014872 patent/WO2016123079A1/en not_active Ceased
- 2016-01-26 KR KR1020177023453A patent/KR102538370B1/ko active Active
- 2016-01-26 AU AU2016211745A patent/AU2016211745A1/en not_active Abandoned
- 2016-01-26 PL PL16704744T patent/PL3250185T3/pl unknown
- 2016-01-26 EP EP22175139.9A patent/EP4082531B1/en active Active
- 2016-01-26 ES ES23196938T patent/ES3031414T3/es active Active
- 2016-01-26 US US15/006,525 patent/US10596107B2/en active Active
- 2016-01-26 EP EP18209003.5A patent/EP3470059B1/en active Active
- 2016-01-26 HU HUE20166312A patent/HUE059639T2/hu unknown
- 2016-01-26 SI SI201631905T patent/SI4268850T1/sl unknown
- 2016-01-26 MX MX2017009699A patent/MX390671B/es unknown
- 2016-01-26 PL PL18209003T patent/PL3470059T3/pl unknown
- 2016-01-26 ES ES16704744T patent/ES2704125T3/es active Active
- 2016-01-26 PL PL20166312.7T patent/PL3721868T3/pl unknown
- 2016-01-26 ES ES20166312T patent/ES2924645T3/es active Active
- 2016-01-26 ES ES22175139T patent/ES2966595T3/es active Active
- 2016-01-26 EP EP16704744.8A patent/EP3250185B1/en not_active Revoked
- 2016-01-26 PT PT231969387T patent/PT4268850T/pt unknown
- 2016-01-26 PL PL23196938.7T patent/PL4268850T3/pl unknown
- 2016-01-26 HU HUE16704744A patent/HUE041945T2/hu unknown
- 2016-01-26 HU HUE22175139A patent/HUE066045T2/hu unknown
- 2016-01-26 PT PT221751399T patent/PT4082531T/pt unknown
- 2016-01-26 BR BR112017016016-1A patent/BR112017016016B1/pt active IP Right Grant
- 2016-01-26 ES ES18209003T patent/ES2787039T3/es active Active
- 2016-01-26 HU HUE23196938A patent/HUE071679T2/hu unknown
- 2016-01-26 CA CA2975106A patent/CA2975106A1/en not_active Abandoned
- 2016-01-26 EP EP20166312.7A patent/EP3721868B2/en active Active
-
2020
- 2020-03-23 US US16/826,366 patent/US11534395B2/en active Active
-
2021
- 2021-05-12 AU AU2021203027A patent/AU2021203027B2/en active Active
-
2022
- 2022-12-21 US US18/086,286 patent/US20230140895A1/en active Pending
-
2023
- 2023-10-12 AU AU2023248145A patent/AU2023248145B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390671B (es) | Composicion de suspension oftalmica. | |
| MX384021B (es) | Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones. | |
| PH12015502587B1 (en) | Ophthalmic nanoemulsion composition containing cyclosporine and method for preparing same | |
| EP4374851A3 (en) | Ophthalmic composition for treatment of dry eye disease | |
| PH12019501902A1 (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| BR112016010067A2 (pt) | partícula de polímero e método de preparação | |
| MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
| NZ719185A (en) | Crystalline forms of therapeutic compounds and uses thereof | |
| CL2017000120A1 (es) | Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares | |
| MX2021006070A (es) | Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo. | |
| MX2016005764A (es) | Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos. | |
| PH12019501999A1 (en) | Pyrazole derivatives as bromodomain inhibitors | |
| MX2021004766A (es) | Composiciones multifásicas. | |
| MY183106A (en) | Fine dry particulate retinoid active agent compostions and topical formulations including the same | |
| EA201890703A1 (ru) | Коллоидные частицы, предназначенные для применения в медицине | |
| BR112015023205A2 (pt) | composições e métodos para formulações de alfavírus vivo atenuado | |
| MX2016009475A (es) | Composiciones efectivas contra la conjuntivitis viral. | |
| MX2018003799A (es) | Nueva composicion oftalmica que contiene rebamipida y metodo para prepararla. | |
| BR112015021000A2 (pt) | composição de uma distribuição liberação prolongada e método de estabilizar proteínas durante o processo de fabricação | |
| EP2962691A4 (en) | AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE POSTERIOR PART OF THE IL CONTAINING A TETRAHYDROPYRANYLAMINOCYCLOPENTYLCARBONYLTETRAHYDROPYRIDOPYRIDINE DERIVATIVE AS ACTIVE INGREDIENT | |
| TH153186A (th) | สูตรผสมชนิดฉีดได้ | |
| MA38521B1 (fr) | Formulation d'acétate d'abiratérone utilisé dans le traitement du cancer de la prostate resistant a la castration | |
| IN2014MU03782A (enExample) | ||
| MA40553B1 (fr) | Derives de pyrimidine eventuellement condensee utiles dans le traitement de maladies inflammatoires, metaboliques, oncologiques et auto-immunes |